Abstract
Pheochromocytomas and extra-adrenal sympathetic paragangliomas show varied histological patterns, and it is difficult to diagnose malignancy or predict the clinical course using current histological criteria. In the present study, we reviewed 146 sympathetic paragangliomas including 116 adrenal (102 unilateral, 14 bilateral) and 30 extra-adrenal tumors including 38 metastatic tumors. We developed a scoring scale according to the following six factors: histological pattern, cellularity, coagulation necrosis, vascular/capsular invasion, Ki-67 immunoreactivity, and types of catecholamine produced. The tumors were classified as well (WD), moderately (MD), and poorly differentiated (PD) types according to their scores. The frequency of these tumor types were 113 WD (77%), 27 MD (19%), and 6 PD (4%). Metastasis was observed in 15 of 113 WD (13%), 17 of 27 MD (63%), and all 6 PD (100%). Five-year survivals of patients with metastases were 92% with WD, 69% with MD, 0% with PD. Respective 10-yr survivals were 83%, 38%, and 0%. Differences between groups were statistically significant. The data show that using this grading scoring system for sympathetic paragangliomas correlates with both metastatic potential and patient survival.
Similar content being viewed by others
References
Kimura N, Capella C, De Krijger RR, et al. Extra-adrenal sympathetic paraganglioma: superior and inferior paraaortic. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, IARC Press, 2004: 164–165.
Medeiros LJ, Wolf BC, Balogh K, Federman M. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 16:580–589, 1985.
Melicow MM. One hundred cases of pheochromocytoma (107 tumors) at the Columbia-Presbyterian Medical Center, 1926–1976. Cancer 40:1987–1999, 1977.
Mornex R, Badet C, Peyrin L. Malignant pheochromocytoma: a series of 14 cases observed between 1996 and 1990. J Endocrinol Invest 15:643–649, 1992.
Kimura N, Sasano N. A comparative study between malignant and benign pheochromocytoma using morphometry, cytophotometry, and immunohistochemistry. In: Lechago J, Kameya T, eds. Endocrine pathology update, Vol. 1. New York, NY: Field & Wood, 1990;99–118.
Kimura N. The adrenal medulla and extra-adrenal paraganglia. In Stefaneanu L, Sasano H, Kovacs K, eds. Molecular and cellular endocrine pathology, London: Arnold, 2000; 253–264.
DeLellis RA. Adrenal medullary tumors. In: Page DL, DeLellis RA, Hough AJ, eds. Tumors of the adrenal, 2nd ed. Washington, DC: AFIP, 1986; 203–206.
Thompson LDR. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms. A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551–566, 2002.
Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202–206, 1989.
Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. In: WHO International Histological Classification of Tumours, 2nd ed. Berlin: Springer Verlag, 1999:1–5.
Noshiro T, Shimizu K, Watanabe T, et al. Changes in clinical features and long-term prognosis in patients with pheochromocytoma. Am J Hypertens 13:35–43, 2000.
Kimura N, Miura W, Noshiro T, Miura Y, Ookuma T, Nagura H. Ki-67 is an indicator of progression of neuroendocrine tumors. Endocr Pathol 5:223–228, 1994.
Yoshida S, Hatori M, Noshiro T, Kimura N, Kokubun S. Twenty-six-years’ survival with multiple bone metastasis of malignant pheochromocytoma. Arch Orthop Trauma Surg 121:598–6000, 2001.
Lloyd RV, Blaivas M, Wilson BS. Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues. Arch Pathol Lab Med 109:633–635, 1985.
Linnoila RI, Keiser HR, Steiberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168–1180, 1990.
Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 15:631–642, 1992.
Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med 115:484–487, 1991.
Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K. Immunohistochemical estimation of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol 12:1107–1111, 1999.
Wong DL. Why is the adrenal adrenergic? Endocr Pathol 14:25–36, 2003.
Kimura N, Miura Y, Nagatsu I, Nagura H. Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchow Archiv A Pathol Anat 421:25–32, 1992.
Kimura N, Togo A, Sugimoto T, et al. Deficiency of phenylethanolamine N-methyltransferase in norepinephrine-producing pheochromocytoma. Endocr Pathol 7:131–136, 1996.
Dannenberg H, Komminoth P, Dinjens WN, Speel EJ, de Kriiger RR. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocr Pathol 14:329–350, 2003.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kimura, N., Watanabe, T., Noshiro, T. et al. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16, 23–32 (2005). https://doi.org/10.1385/EP:16:1:023
Issue Date:
DOI: https://doi.org/10.1385/EP:16:1:023